IntraOp is excited to share the results for ultra-high Dose Rate FLASH radiotherapy survival and toxicity in independent murine studies by MD Anderson Cancer Center in Houston, TX, and University Hospital of Lausanne in Lausanne, Switzerland, made possible by the IntraOp Mobetron with FLASH-IQ.*
This independent study also validates the robustness of the FLASH-IQ platform in reproducible FLASH effects. The study’s findings suggest that “… using beam parameters that are known to evoke FLASH effects can lead to responses that are robust and reproducible across machines and institutions…” (Bourhis et al.). We are proud to support these seminal investigational studies with the stability, linearity, and reproducibility of IntraOp Mobetron with FLASH-IQ.
*Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not currently cleared for sale by the US FDA.